AN2 Therapeutics (ANTX) Cash & Equivalents (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Cash & Equivalents for 6 consecutive years, with $53.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 167.64% year-over-year to $53.5 million; the TTM figure through Mar 2026 stood at $53.5 million (up 167.64% YoY), while the FY2025 annual figure was $19.9 million, down 6.6% from the prior year.
• Cash & Equivalents improved to $53.5 million in Q1 2026 per ANTX's latest filing, from $19.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $82.5 million in Q1 2022 and bottomed at $15.6 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $31.2 million across 5 years, with a median of $26.8 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 67.63% — and 2026, when it soared 167.64%.
• AN2 Therapeutics' Cash & Equivalents stood at $27.2 million in 2022, then slumped by 42.51% to $15.6 million in 2023, then surged by 36.45% to $21.4 million in 2024, then fell by 6.6% to $19.9 million in 2025, then soared by 168.23% to $53.5 million in 2026.
• Business Quant data shows ANTX's Cash & Equivalents at $53.5 million in Q1 2026, $19.9 million in Q4 2025, and $18.0 million in Q3 2025.